PARP1-IN-30, with the CAS number 908803-38-3, is a small molecule inhibitor specifically targeting the enzyme poly(ADP-ribose) polymerase 1 (PARP1). This compound is primarily studied for its potential therapeutic applications in cancer treatment, particularly in tumors with deficiencies in DNA repair mechanisms, such as those with BRCA mutations. PARP1 plays a crucial role in the cellular response to DNA damage, and its inhibition can lead to the accumulation of DNA lesions, ultimately resulting in cancer cell death. Characteristics of PARP1-IN-30 include its ability to selectively bind to the PARP1 enzyme, thereby blocking its activity and disrupting the repair of single-strand breaks in DNA. This selective inhibition can enhance the efficacy of certain chemotherapeutic agents and is being explored in combination therapies. Additionally, the compound's pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are critical for its development as a therapeutic agent. Ongoing research aims to further elucidate its mechanism of action and optimize its use in clinical settings.

PARP1-IN-30

908803-38-3: PARP1-IN-30, with the CAS number 908803-38-3, is a small molecule inhibitor specifically targeting the enzyme poly(ADP-ribose) polymerase 1 (PARP1). This compound is primarily studied for its potential therapeutic applications in cancer treatment, particularly in tumors with deficiencies in DNA repair mechanisms, such as those with BRCA mutations. PARP1 plays a crucial role in the cellular response to DNA damage, and its inhibition can lead to the accumulation of DNA lesions, ultimately resulting in cancer cell death. Characteristics of PARP1-IN-30 include its ability to selectively bind to the PARP1 enzyme, thereby blocking its activity and disrupting the repair of single-strand breaks in DNA. This selective inhibition can enhance the efficacy of certain chemotherapeutic agents and is being explored in combination therapies. Additionally, the compound's pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are critical for its development as a therapeutic agent. Ongoing research aims to further elucidate its mechanism of action and optimize its use in clinical settings.

<p>PARP1-IN-30 is a specific and effective PARP1 inhibitor with cytotoxic properties. It precisely inhibits PARP1 in tumor cells lacking breast cancer 1 protein (BRCA1) or BRCA2. PARP1-IN-30 holds potential for use in cancer research.</p>

CAS 908803-38-3

PARP1-IN-30

PARP1-IN-30

Ref: TM-T200644